# Nuplazid

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/nuplazid
Canonical HTML page: https://getbiobrief.com/entity/nuplazid

## Timeline

- **2026-02-25**: Q4 Earnings Call — ACADIA reports strong year-end results and 2026 guidance.
- **2025-11-15**: Daybue Stix Launch — Launch of the granule formulation to enhance patient compliance.
- **2023-03-10**: Daybue Approval — FDA approves Daybue as the first treatment for Rett syndrome.
- **2016-05-01**: Nuplazid Approval — FDA approves Nuplazid for Parkinson's disease psychosis.

## Recent coverage (1 stories)

### ACADIA Pharmaceuticals Solidifies Rare Disease Leadership in Q4 Results
2026-02-27 12:48:03 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

ACADIA Pharmaceuticals delivered a strong Q4 performance, underscored by the rapid adoption of Daybue and the resilience of its Parkinson’s franchise. The results highlight a successful transition into a diversified commercial-stage biotech with a clear path to sustained profitability.
Full story: https://getbiobrief.com/story/acadia-pharmaceuticals-q4-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.